Practical approaches for the treatment of chronic heart failure: Frequently asked questions, overlooked points and controversial issues in current clinical practice

Abstract

Practical approaches for the treatment of chronic heart failure:Frequently asked questions, overlooked points and controversial issues in current clinical practiceHeart failure (HF) is a progressive disorder associated with impaired quality of life, high morbidity, mortality and frequent hospitalization and affects millions of people from all around the world. Despite further improvements in HF therapy, mortality and morbidity remains to be very high. The life-long treatment, frequent hospitalization, and sophisticated and very expensive device therapies for HF also leads a substantial economic burden on the health care system. Therefore, implementation of evidence-based guideline-recommended therapy is very important to overcome its worse clinical outcomes. However, HF therapy is a long process that has many drawbacks and sometimes HF guidelines cannot answers to every question which rises in everyday clinical practice. In this paper, commonly encountered questions, overlooked points, controversial issues, management strategies in grey zone and problems arising during follow up of a HF patient in real life clinical practice have been addressed in the form of expert opinions based on the available data in the literature. (Anatol J Cardiol 2015: 15 Suppl 2; 1-60)

Drug therapy problems and contributing factors in the management of heart failure patients in Jimma University Specialized Hospital, Southwest Ethiopia

“…Heart failure (HF) is a progressive and complex clinical syndrome that can occur due to impairment of cardiac structure or function that leads to the inability of the heart to fill with or pump sufficient amount of blood to meet the metabolic need of the body [ 1 – 3 ]. HF is a major public health problem that affects about 26 million peoples worldwide [ 4 , 5 ]. In spite of effective pharmacotherapy, HF remains the leading cause of morbidity, mortality and economic burden for health care budgets [ 6 , 7 ].…”

Personalized Prognostic Evaluation of the Effectiveness of Metoprolol Succinate in the Complex Treatment of Patients with Heart Failure and Obesity

“…Існуючі на даний момент настанови до базисних груп у лікуванні СН відносять бета-адреноблокатори, інгібітори ангіотензинперетворюючого фермента (АПФ) та антагоністи мінералокортикоїдних рецепторів (МР). Вони мають найвищий клас рекомендацій та рівня доказовості [14,15].…”